The European Community (EC) plans to create a single market for pharmaceutical medicines, but the drug industry is closely linked to cultural and societal values concerning health; to the national regulatory agencies responsible for the evaluation of safety, quality, and efficacy of new drugs; to multinational and domestic companies competing in national and international markets; and to varied interest groups of professionals and consumers organized along national and multinational lines. We review the history of the EC's policy proposals, examine reactions from all these interested parties, and assess the prospects for integration into a single market. The contentious debate that continues among the parties over national prerogatives, industrial interests, professional mandates, and consumer concerns clouds the prospects for a system of centralized drug registration that will be acceptable to all EC member states.
Skip Nav Destination
Research Article| August 01 1992
Pharmaceutical Regulation in the European Community: Barriers to Single Market Integration
Louis H. Orzack;
Kenneth I. Kaitin;
J Health Polit Policy Law (1992) 17 (4): 847–868.
Louis H. Orzack, Kenneth I. Kaitin, Louis Lasagna; Pharmaceutical Regulation in the European Community: Barriers to Single Market Integration. J Health Polit Policy Law 1 August 1992; 17 (4): 847–868. doi: https://doi.org/10.1215/03616878-17-4-847
Download citation file:
Don't already have an account? Register
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your InstitutionSign In
Citing articles via
Emergent Patterns in the Regulation of Pharmaceuticals: Institutions and Interests in the United States, Canada, Britain, and France
How the Pace of Change Affects the Scope of Reform: Pharmaceutical Insurance in Canada, Australia, and the United Kingdom